Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.56 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.56 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.54 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.54 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | PNP | P00491 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | POLA1 | P09884 | 1/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanosine SCHEMBL4879720 | 0.93 | P2RY2 (0.59) | POLBADRB1DNMT1P2RY2P2RY4 | |
| Deoxyguanosine SCHEMBL20445785 | 0.92 | POLB (0.67) | POLBADRB1DNMT1P2RY2P2RY4 | |
| Deoxyguanosine SCHEMBL14208980 | 0.91 | POLB (0.67) | POLBADRB1DNMT1P2RY2P2RY4 | |
| Deoxyguanosine SCHEMBL9396414 | 0.91 | POLB (0.67) | POLBADRB1DNMT1P2RY2P2RY4 | |
| Deoxyguanosine SCHEMBL13318963 | 0.91 | POLB (0.67) | POLBADRB1DNMT1P2RY2P2RY4 | |
| Deoxyguanosine SCHEMBL22992402 | 0.91 | POLB (0.67) | POLBADRB1DNMT1P2RY2P2RY4 | |
| Deoxyguanosine SCHEMBL10068103 | 0.91 | POLB (0.67) | POLBADRB1DNMT1P2RY2P2RY4 | |
| Deoxyguanosine SCHEMBL23892102 | 0.91 | POLB (0.67) | POLBADRB1DNMT1P2RY2P2RY4 | |
| Deoxyguanosine SCHEMBL23225364 | 0.91 | POLB (0.67) | POLBADRB1DNMT1P2RY2P2RY4 | |
| Deoxyguanosine SCHEMBL20615 | 0.91 | POLB (0.67) | POLBADRB1DNMT1P2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101253190-A | beta-L-N4-hydroxycytosine deoxynucleosides and their use as pharmaceutical agents for the prophylaxis and treatment of viral diseases | MAX DELBRUECK CT (DE) | 2008-08-27 | — | — | CN | claimed |
| CN-117693357-A | Cancer vaccine based on induced pluripotent stem cells | 克洛里斯生物科学有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117138146-A | Method and device for purifying blood against circulating cell-free DNA | 圣特萨斯股份公司 | 2023-12-01 | — | — | CN | disclosed |
| EP-4265737-A1 | METHYLATION MARKERS FOR PREDICTING SENSITIVITY TO TREATMENT WITH ANTIBODY BASED THERAPY | Academisch Medisch Centrum (NL) | 2023-10-25 | — | — | EP | disclosed |
| US-11771811-B2 | Method and device for purification of blood from circulating cell free DNA | SANTERSUS AG (CH) | 2023-10-03 | — | — | US | disclosed |
| US-11771812-B2 | Method and device for purification of blood from circulating cell free DNA | SANTERSUS AG (CH) | 2023-10-03 | — | — | US | disclosed |
| CN-111433605-B | Method and device for purifying blood against circulating cell-free DNA | 圣特萨斯股份公司 | 2023-09-08 | — | — | CN | disclosed |
| US-11724015-B2 | Method and device for purification of blood from circulating cell free DNA | SANTERSUS AG (CH) | 2023-08-15 | — | — | US | disclosed |
| US-20230218810-A1 | METHOD AND DEVICE FOR PURIFICATION OF BLOOD FROM CIRCULATING CELL FREE DNA | SANTERSUS AG (CH) | 2023-07-13 | — | — | US | disclosed |
| US-20230218809-A1 | METHOD AND DEVICE FOR PURIFICATION OF BLOOD FROM CIRCULATING CELL FREE DNA | SANTERSUS AG (CH) | 2023-07-13 | — | — | US | disclosed |
| EP-3685165-A1 | METHOD AND DEVICE FOR PURIFICATION OF BLOOD FROM CIRCULATING CELL FREE DNA | Santersus AG (CH) | 2020-07-29 | — | — | EP | disclosed |
| CN-111433605-A | Method and apparatus for purifying blood against circulating cell-free DNA | 圣特萨斯股份公司 | 2020-07-17 | — | — | CN | disclosed |
| WO-2019053243-A1 | METHOD AND DEVICE FOR PURIFICATION OF BLOOD FROM CIRCULATING CELL FREE DNA | SANTERSUS SA (CH) | 2019-03-21 | — | — | WO | disclosed |
| EP-3168310-A1 | METHYLATION MARKERS FOR COLORECTAL CANCER | Academisch Medisch Centrum (NL) | 2017-05-17 | — | — | EP | disclosed |
| WO-2013064163-A1 | METHYLATION MARKERS FOR COLORECTAL CANCER | ACADEMISCH MEDISCH CENTRUM (NL) | 2013-05-10 | — | — | WO | disclosed |
| US-20110244025-A1 | MODIFIED OLIGORIBONUCLEOTIDE ANALOGS WITH ENHANCED IMMUNOSTIMULATORY ACTIVITY | ZOETIS BELGIUM SA (BE) | 2011-10-06 | — | — | US | disclosed |
| WO-2009079208-A2 | METHYLATION MARKERS FOR CANCER | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2009-06-25 | — | — | WO | disclosed |
| EP-1899467-A2 | MODIFIED OLIGORIBONUCLEOTIDE ANALOGS WITH ENHANCES IMMUNOSTIMULATORY ACTIVITY | Coley Pharmaceutical GmbH (DE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006116458-A2 | MODIFIED OLIGORIBONUCLEOTIDE ANALOGS WITH ENHANCES IMMUNOSTIMULATORY ACTIVITY | COLEY PHARMACEUTICAL GMBH (DE) | 2006-11-02 | — | — | WO | disclosed |
| US-20060241076-A1 | Modified oligoribonucleotide analogs with enhanced immunostimulatory activity | COLEY PHARMACEUTICAL GMBH (DE) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241076-A1 | Modified oligoribonucleotide analogs with enhanced immunostimulatory activity | TLR3, TLR8, TLR9 | POLB 229/4885ADRB1 3697/4885DNMT1 444/4885 |
| US-20110244025-A1 | MODIFIED OLIGORIBONUCLEOTIDE ANALOGS WITH ENHANCED IMMUNOSTIMULATORY ACTIVITY | TLR3, TLR9, TLR8 | POLB 226/4885ADRB1 3691/4885DNMT1 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.